Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam™ (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris.
BenzEFoam™ Emollient Foam is formulated to address the needs of patients with body acne and to offer an ideal treatment option for them. BenzEFoam™ is spread easily over the extensive skin areas of the chest and back, where body acne symptoms most often occur. BenzEFoam™ has demonstrated low rates of cutaneous irritation and dryness in clinical trials.
BenzEFoam™ Emollient Foam is proven to be very effective in reducing the acne-causing bacteria P. acnes, on the back. In a clinical trial, BenzEFoam demonstrated a greater than 100-fold reduction in P. acnes counts after two weeks of use.
“Benzoyl peroxide is a mainstay of acne treatment. Dermatologists have been waiting for a foam formulation of benzoyl peroxide,” said Dr. Hilary Baldwin, Vice Chair and Associate Professor, Department of Dermatology, State University of New York (SUNY)-Brooklyn. “We believe patients prefer and are more compliant with applying foam formulations for skin conditions affecting broad body areas. BenzEFoam™ is a good treatment option for chest and back acne, as well as for acne in hairy areas.”